Bevacizumab, ranibizumab offer comparable results, Austrian study shows
HAMBURG — Avastin has comparable efficacy to Lucentis, according to the results of a multicentered study carried out in Austria.
The MANTA study was a doulbe-masked, prospective multicenter trial, self-financed by the participating centers with the contribution of the Austrian government.
“It was a non-inferiority study based on the data of MARINA, ANCHOR and FOCUS trials. A total of 320 patients with neovascular AMD were included and randomized to treatment with either 0.5 ranibizumab or 1.25mg bevacizumab. After three initial monthly injections, patients were seen monthly and treated as-needed,” Ilse Krebs, MD, study coordinator, said at the Euretina meeting.
Results showed a comparable distance visual acuity increase, with patients gaining on average 4.9 lines with Avastin (bevacizumab, Genentech/Roche) and 4.1 lines with Lucentis (ranibizumab, Genentech/Novartis). A similar pattern of steep increase up to 3-4 month was also observed with the two drugs.
“There was no significant difference. The VA increase was faster with Lucentis, but Lucentis also had the higher number of eyes loosing lines, and overall VA results were better in the Avastin group,” Krebs said.
Ocular and systemic adverse events were comparable in the two groups.